Von Hippel-Lindau Disease Clinical Trials

32 clinical trials for Von Hippel-Lindau Disease across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) — RECRUITING · PHASE3
• Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) — RECRUITING · PHASE2
• Use of Tracking Devices to Locate Abnormalities During Invasive Procedures — RECRUITING · NA
• Data Collection Protocol for Patients With Von Hippel Lindau Disease — RECRUITING
• Familial Investigations of Childhood Cancer Predisposition — RECRUITING
• 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors — RECRUITING · NA
• Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors — RECRUITING · PHASE2
• Institutional Registry of Rare Diseases — RECRUITING
• Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial — RECRUITING · PHASE2
• Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients — RECRUITING
• MyVHL: Patient Natural History Study — RECRUITING
• Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells — RECRUITING
• Propranolol and Von Hippel-Lindau Disease — RECRUITING · NA
• Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients — RECRUITING
• Pediatric Von Hippel-Lindau Disease: Natural History, Predictive Factors, and Long-Term Functional Outcomes of Central Nervous System Hemangioblastomas — NOT_YET_RECRUITING
• Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease — ACTIVE_NOT_RECRUITING · NA
• Interdisciplinary Care and Systemic Therapy in von Hippel–Lindau Disease – A Prospective Single-Center Observational Study on the Clinical Use of Belzutifan at Ulm University Hospital — NOT_YET_RECRUITING
• Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma — COMPLETED
• Precision Medicine for Neurocutaneous Syndromes in Western China — COMPLETED
• MSD Belzutifan PAS — WITHDRAWN
• MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) — COMPLETED · PHASE2
• Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease — COMPLETED
• 68Ga-NY104 PET/CT in Von Hippel-Lindau Disease — OTHER · PHASE2
• A Study of BPI-452080 in Subjects With Solid Tumors — OTHER · PHASE1
• Von Hippel-Lindau Disease Genetic Epidemiology Study — TERMINATED
• Drivers of Hypoxia-induced Angiogenesis in Tumor Development — OTHER
• Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease — COMPLETED
• Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) — COMPLETED · PHASE1
• Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 — COMPLETED · PHASE2
• Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy — COMPLETED · PHASE1
• Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease — COMPLETED · PHASE2
• Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease — TERMINATED · PHASE1

Refine this search